5 recruiting, 2 active not recruiting, 2 completed, 2 unknown. 6 Phase 2, 3 Phase 1, 2 Early Phase 1, 2 Not applicable.
Follow Resectable Pancreatic Ductal Adenocarcinoma: new trials by email Literature Review of Resectable Pancreatic Ductal Adenocarcinoma trials Research Report on Resectable Pancreatic Ductal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy - Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | University of Washington | 15 | 2026-10-15 | 2026-09-21 |
| Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment Genetic testing, Optional biopsy, Tissue collection - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Not applicable | Recruiting | British Columbia Cancer Agency | 200 | 2025-11-28 | 2026-09-16 |
| Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy Non-Interventional Study - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Recruiting | Emory University | 87 | 2024-08-05 | 2025-08-01 | |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study Cisplatin, Fluorouracil, Gemcitabine - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-04-18 | 2026-05-04 | |
| Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography - Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 130 | 2022-11-15 | 2026-08-10 |
| A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer Pyrvinium Pamoate - Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8 | Phase 1 | Active not recruiting | Thomas Jefferson University | 20 | 2021-07-29 | 2026-07-21 |
| Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy Standardized surveillance - Resectable Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma | Not applicable | Enrolling by invitation | UMC Utrecht | 306 | 2021-03-16 | 2024-09-19 |
| NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2020-07-01 | 2026-05-22 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer Cobimetinib, Olaparib, Onvansertib - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Recruiting | OHSU Knight Cancer Institute | 90 | 2019-08-01 | 2026-09-04 |
| Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Fluorouracil, Irinotecan, Irinotecan Hydrochloride - Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 28 | 2019-07-24 | 2024-08-09 |
| Nalirinox Neo-pancreas RAS Mut ctDNA Study NALRINOX combination - Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Unknown | Fundación de investigación HM | 20 | 2019-05-01 | 2022-08-02 |
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Metformin Hydrochloride 500Mg Tablet - Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Unknown | British Columbia Cancer Agency | 20 | 2019-01-01 | 2018-01-18 |
| A Phase II Study of Neoadjuvant FOLFIRINOX FOLFIRINOX - Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | Indiana University | 48 | 2014-06-03 | 2022-04-19 |
Pancreatic Neoplasms (5) · Neoplasms (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Pancreatic Diseases (5)
Fluorouracil (4) · Irinotecan (4) · Leucovorin (4) · Oxaliplatin (4) · Radiation (3) · Radiotherapy (3) · dehydroftorafur (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Gemcitabine (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Taxes (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · AZD5305 (1)
British Columbia Cancer Agency (2) · M.D. Anderson Cancer Center (2) · Emory University (1) · Fundación de investigación HM (1) · Indiana University (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Thomas Jefferson University (1) · UMC Utrecht (1) · University of Washington (1)
United States (9) · Canada (2) · Netherlands (1) · Spain (1) · United Kingdom (1)
Daniel J Renouf, MD (2) · Eugene J Koay (2) · Ajit H. Goenka, M.D. (1) · Andrew Coveler, MD (1) · Antonio Cubillo, MD (1) · Brett L Ecker, MD (1) · Charles D Lopez (1) · H. C. van Santvoort, MD, PhD (1) · Harish Lavu, MD (1) · I. Q. Molenaar, MD, PhD (1) · L. A. Daamen, MD, PhD (1) · M. G.H. Besselink, MD, PhD (1) · Michael House, M.D. (1) · Mihir M Shah (1) · Zev A Wainberg (1)
PMID 34980020, PMID 37848297, PMID 38902836
P30CA060553 (1), P30CA138292 (1), R01CA272628 (1)